Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126404041 | 12640404 | 1 | I | 20160803 | 20160810 | 20160810 | EXP | JP-TEVA-683006ACC | TEVA | KAWAKAMI T,HIRABAYASHI Y,KAWAKAMI F,ISOBE R,KANEKO N,MIMURA Y. | 80.00 | YR | M | Y | 0.00000 | 20160810 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126404041 | 12640404 | 1 | PS | BENDAMUSTINE HYDROCHLORIDE. | BENDAMUSTINE HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | 22249 | POWDER FOR INJECTION | ||||||||||
| 126404041 | 12640404 | 2 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | (6 CYCLES) | 89081 | ||||||||||
| 126404041 | 12640404 | 3 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 30 MILLIGRAM DAILY; | 89081 | 30 | MG | QD | |||||||
| 126404041 | 12640404 | 4 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 89081 | 30 | MG | QOD | ||||||||
| 126404041 | 12640404 | 5 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | 20 MILLIGRAM DAILY; | 89081 | 20 | MG | QD | |||||||
| 126404041 | 12640404 | 6 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | Unknown | (2 CYCLES) | 77983 | ||||||||||
| 126404041 | 12640404 | 7 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | (2 CYCLES) | 0 | |||||||||||
| 126404041 | 12640404 | 8 | SS | CISPLATIN. | CISPLATIN | 1 | Unknown | (2 CYCLES) | 74656 | ||||||||||
| 126404041 | 12640404 | 9 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Oral | 74284 | 50 | MG | QOD | ||||||||
| 126404041 | 12640404 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Oral | 74284 | /wk | ||||||||||
| 126404041 | 12640404 | 11 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | (6 CYCLES) | 0 | INJECTION | |||||||||
| 126404041 | 12640404 | 12 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | (6 CYCLES) | 0 | ||||||||||
| 126404041 | 12640404 | 13 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | (2 CYCLES, R-GDP) | 0 | ||||||||||
| 126404041 | 12640404 | 14 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | (2 CYCLES, R-GDP) | 0 | ||||||||||
| 126404041 | 12640404 | 15 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | (6 CYCLES) | 0 | ||||||||||
| 126404041 | 12640404 | 16 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | 0 | 50 | MG | QOW | ||||||||
| 126404041 | 12640404 | 17 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Oral | 0 | /wk | ||||||||||
| 126404041 | 12640404 | 18 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | (6 CYCLES) | 0 | ||||||||||
| 126404041 | 12640404 | 19 | SS | PROCARBAZINE | PROCARBAZINE | 1 | Oral | 0 | 50 | MG | QOD | ||||||||
| 126404041 | 12640404 | 20 | SS | PROCARBAZINE | PROCARBAZINE | 1 | Oral | 0 | /wk | ||||||||||
| 126404041 | 12640404 | 21 | SS | OSELTAMIVIR | OSELTAMIVIR | 1 | Oral | 75 MILLIGRAM DAILY; | 0 | 75 | MG | QD | |||||||
| 126404041 | 12640404 | 22 | SS | OSELTAMIVIR | OSELTAMIVIR | 1 | Oral | 150 MILLIGRAM DAILY; | 0 | 75 | MG | BID | |||||||
| 126404041 | 12640404 | 23 | SS | OSELTAMIVIR | OSELTAMIVIR | 1 | Oral | 150 MILLIGRAM DAILY; | 0 | 75 | MG | BID | |||||||
| 126404041 | 12640404 | 24 | SS | PERAMIVIR | PERAMIVIR | 1 | Intravenous (not otherwise specified) | 0 | 300 | MG | |||||||||
| 126404041 | 12640404 | 25 | SS | PERAMIVIR | PERAMIVIR | 1 | Intravenous (not otherwise specified) | 0 | 300 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126404041 | 12640404 | 1 | Lymphoma |
| 126404041 | 12640404 | 2 | Lymphoma |
| 126404041 | 12640404 | 6 | Lymphoma |
| 126404041 | 12640404 | 7 | Lymphoma |
| 126404041 | 12640404 | 8 | Lymphoma |
| 126404041 | 12640404 | 9 | Lymphoma |
| 126404041 | 12640404 | 11 | Lymphoma |
| 126404041 | 12640404 | 12 | Lymphoma |
| 126404041 | 12640404 | 15 | Lymphoma |
| 126404041 | 12640404 | 18 | Lymphoma |
| 126404041 | 12640404 | 19 | Lymphoma |
| 126404041 | 12640404 | 21 | Prophylaxis |
| 126404041 | 12640404 | 22 | Influenza |
| 126404041 | 12640404 | 24 | Influenza |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126404041 | 12640404 | OT |
| 126404041 | 12640404 | HO |
| 126404041 | 12640404 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126404041 | 12640404 | Influenza | |
| 126404041 | 12640404 | Pathogen resistance | |
| 126404041 | 12640404 | Vaccine virus shedding |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126404041 | 12640404 | 3 | 201412 | 0 | ||
| 126404041 | 12640404 | 4 | 201501 | 0 | ||
| 126404041 | 12640404 | 5 | 201501 | 0 | ||
| 126404041 | 12640404 | 9 | 201501 | 0 | ||
| 126404041 | 12640404 | 10 | 201502 | 0 | ||
| 126404041 | 12640404 | 16 | 201501 | 0 | ||
| 126404041 | 12640404 | 17 | 201502 | 0 | ||
| 126404041 | 12640404 | 19 | 201501 | 0 | ||
| 126404041 | 12640404 | 20 | 201502 | 0 | ||
| 126404041 | 12640404 | 21 | 201501 | 0 | ||
| 126404041 | 12640404 | 22 | 201501 | 0 | ||
| 126404041 | 12640404 | 23 | 201502 | 0 | ||
| 126404041 | 12640404 | 24 | 201502 | 0 | ||
| 126404041 | 12640404 | 25 | 201502 | 0 |